About Us

BioSante is focused on developing innovative testosterone and estrogen products for female sexual health, menopause, contraception and male hypogonadism. BioSante's lead products are LibiGel^® (testosterone gel) in development under an SPA, to treat female sexual dysfunction, and Elestrin™ (estradiol gel), FDA approved to treat hot flashes in menopausal women. The current market for testosterone and estrogen products is approximately $2.5 billion dollars in the U.S. alone, with estimates for female sexual dysfunction potentially adding more than $2.0 billion, and the current market for hormonal contraception is approximately $3.0 billion.

The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery systems and aesthetic medicine (BioLook™).